BioLife Solutions (BLFS) versus Johnson & Johnson (JNJ) Critical Analysis
BioLife Solutions (NASDAQ: BLFS) and Johnson & Johnson (NYSE:JNJ) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, dividends, earnings and risk.
Volatility and Risk
BioLife Solutions has a beta of 0.32, suggesting that its stock price is 68% less volatile than the S&P 500. Comparatively, Johnson & Johnson has a beta of 0.74, suggesting that its stock price is 26% less volatile than the S&P 500.
This is a summary of recent ratings and price targets for BioLife Solutions and Johnson & Johnson, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Johnson & Johnson||4||6||8||0||2.22|
BioLife Solutions currently has a consensus price target of $6.50, indicating a potential upside of 37.42%. Johnson & Johnson has a consensus price target of $145.59, indicating a potential upside of 11.66%. Given BioLife Solutions’ stronger consensus rating and higher probable upside, equities research analysts plainly believe BioLife Solutions is more favorable than Johnson & Johnson.
Institutional & Insider Ownership
9.2% of BioLife Solutions shares are owned by institutional investors. Comparatively, 65.7% of Johnson & Johnson shares are owned by institutional investors. 36.8% of BioLife Solutions shares are owned by company insiders. Comparatively, 0.2% of Johnson & Johnson shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Johnson & Johnson pays an annual dividend of $3.36 per share and has a dividend yield of 2.6%. BioLife Solutions does not pay a dividend. Johnson & Johnson pays out 861.5% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. BioLife Solutions has raised its dividend for 55 consecutive years.
Valuation & Earnings
This table compares BioLife Solutions and Johnson & Johnson’s gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|BioLife Solutions||$8.23 million||8.06||-$6.87 million||($0.42)||-11.26|
|Johnson & Johnson||$76.45 billion||4.58||$1.30 billion||$0.39||334.33|
Johnson & Johnson has higher revenue and earnings than BioLife Solutions. BioLife Solutions is trading at a lower price-to-earnings ratio than Johnson & Johnson, indicating that it is currently the more affordable of the two stocks.
This table compares BioLife Solutions and Johnson & Johnson’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Johnson & Johnson||1.70%||27.80%||13.26%|
Johnson & Johnson beats BioLife Solutions on 10 of the 16 factors compared between the two stocks.
BioLife Solutions Company Profile
BioLife Solutions, Inc. (BioLife) is engaged in the developing, manufacturing and marketing a portfolio of biopreservation tools and services for cells, tissues and organs, including clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related cloud hosted biologistics cold chain management application for shippers. The Company’s product offerings include hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs; generic blood stem cell freezing and cell thawing media products; custom product formulation and custom packaging services; cold chain logistics services incorporating precision thermal packaging products and cloud-hosted Web applications, and contract aseptic manufacturing formulation, fill and finish services of liquid media products. Its products include HypoThermosol FRS, CryoStor, BloodStor, Cell Thawing Media, PrepaStor and biologistex cold-chain management service.
Johnson & Johnson Company Profile
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women’s health and wound care markets. The Pharmaceutical segment is focused on five therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, and cardiovascular and metabolic diseases. The Medical Devices segment includes a range of products used in the orthopedic, surgery, cardiovascular, diabetes care and vision care fields. Its research facilities are located in the United States, Belgium, Brazil, Canada, China, France, Germany, India, Israel, Japan, the Netherlands, Singapore, Switzerland and the United Kingdom.
Receive News & Ratings for BioLife Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLife Solutions and related companies with MarketBeat.com's FREE daily email newsletter.